stockrow
Friday 6 November 2026
Export XERS’s income statement to Excel — free account
Xeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
15.16
2.08
+15.90%
Follow XERS
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 78.59 | 2,065.79 |
+8 more quarters Free account |
P/S ratio |
4.70 | 4.08 | 3.14 | 4.32 | |
P/FCF ratio |
23.79 | 24.59 | 20.81 | 45.09 | |
P/Operating CF |
48.77 | 165.65 | 100.21 | 62.83 | |
P/B ratio |
35.46 | 0.00 | 76.02 | 92.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.03 | 4.47 | 3.53 | 4.73 | |
EV/EBITDA |
35.01 | 28.35 | 21.32 | 33.70 | |
EV/Operating CF |
25.15 | 26.49 | 22.88 | 48.23 | |
EV/FCF |
25.47 | 26.94 | 23.37 | 49.43 | |
Quick Ratio |
1.48 | 0.95 | 1.42 | 1.48 | |
Current Ratio |
2.15 | 1.45 | 2.12 | 2.19 | |
Net Debt/EBITDA |
0.00 | 14.08 | 9.11 | 5.25 | |
Debt/Assets |
44.83% | 61.32% | 56.43% | 57.45% | |
Debt/Equity |
3.89 | (25.95) | 17.00 | 16.10 | |
Asset Turnover |
0.93 | 0.90 | 0.89 | 0.83 | |
Operating CF/Net income |
3.14 | (0.27) | 4.42 | 1.81 | |
Capex/Depreciation |
— | (0.05) | (0.08) | (0.08) | |
Interest Coverage |
2.62 | 0.74 | 1.15 | 2.34 | |
Research and Development Expense of Revenue |
10.31% | 11.58% | 10.57% | 9.18% | |
Selling, General and Administrative Expense of Revenue |
59.79% | 66.27% | 63.93% | 55.36% | |
Intangible Assets out of Total Assets |
0.24 | 0.26 | 0.28 | 0.29 | |
Share Based Compensation of Revenue |
10.07% | 12.02% | 4.98% | 6.14% | |
Graham Net Nets |
(0.05) | (0.11) | (0.13) | (0.10) | |
Graham Number |
0.00 | 0.35 | 0.36 | 0.09 | |
Earnings Yield |
(0.42%) | (1.21%) | 1.27% | 0.05% | |
Free Cash Flow Yield |
4.20% | 4.07% | 4.80% | 2.22% | |
Revenue per Share |
0.59 | 0.53 | 0.49 | 0.53 | |
Operating CF per Share |
0.20 | 0.05 | 0.06 | 0.12 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.20 | 0.05 | 0.06 | 0.12 | |
Cash per Share |
0.72 | 0.70 | 0.66 | 0.69 | |
Shareholders Equity per Share |
0.27 | (0.06) | 0.08 | 0.09 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.27 | (0.06) | 0.08 | 0.09 | |
Free Cash Flow |
35.47 | 8.05 | 9.55 | 19.71 | |
Working Capital |
154.79 | 85.19 | 133.09 | 130.74 | |
Capital Expenditures |
— | (0.21) | (0.32) | (0.33) | |
Net Current Asset Value |
(85.17) | (146.88) | (127.32) | (129.52) | |
EV/EBIT |
39.59 | 40.98 | 30.93 | 55.45 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
36.98 | 37.40 | 27.55 | 50.58 | |
| Other line items | |||||
Average Receivables |
61.17 | 55.58 | 51.31 | 45.73 | |
Average Payables |
7.28 | 9.40 | 8.91 | 2.68 | |
Average Inventory |
72.19 | 74.11 | 63.46 | 58.42 | |
Average Assets |
396.71 | 373.30 | 353.73 | 353.29 | |
Average Common Equity |
23.96 | (14.52) | (11.06) | (7.96) |
Columns are period end dates · fundamentals updated 5 Nov 2026